Epigenomics makes breast cancer test inroads
This article was originally published in Clinica
Executive Summary
Epigenomics has taken an important step towards developing a breast cancer pharmacodiagnostic for providing more individualised therapy, after reporting positive results from studies of its DNA methylation markers for predicting the likelihood of the disease recurring.